The prevalence of RET/PTC rearrangements in papillary thyroid carcinomas (PTCs) varies widely in different studies, and an association of RET/PTC presence with tumor behavior remains to be clarified. A prospective study of 50 adult PTCs examined, using RT-PCR, the prevalence of the 3 main RET rearrangements and also of RET tyrosine kinase (TK) domain sequence expression. The genetic findings were correlated with the MACIS clinical prognostic score and with individual clinical parameters. Three of the patients had been exposed to radiation in childhood or adolescence. Four of the PTCs contained RET/PTC1, confirmed by sequencing, and none contained RET/PTC2 or RET/PTC3. The prevalence of RET rearrangements overall was 8%, but in the subgroup of 3 radiation-exposed patients it was 66.6%. Interestingly, RET tyrosine kinase domain messenger ribonucleic acid was detectable in 70% of PTCs using RET exon 12/13 primers and was detectable in 24% of PTCs using RET exon 15/17 primers. RT-PCR for calcitonin and RET extracellular domain, however, was negative. There was no association between the presence or absence of RET/PTC in the patient's tumor and clinical parameters. We conclude that RET/PTC1 is the predominant rearrangement in PTCs from adults with a history of external irradiation in childhood. RET TK messenger ribonucleic acid expression is common in PTCs, using RT-PCR, and cannot be used to infer the presence of specific RET rearrangements or of RET activation. (J Clin Endocrinol Metab 83: [3631][3632][3633][3634][3635] 1998) 
T HE RET protooncogene encodes a tyrosine kinase cell surface receptor and has an important role in the pathogenesis of some thyroid tumors. RET/PTCs are rearranged forms of RET found in papillary thyroid carcinoma (PTC) (1, 2) , and they comprise three main forms (3) (4) (5) (6) (7) . Two variations of RET/PTC3 have been described (8, 9) ; one is designated RET/PTC4 (8) , and RET/PTC5 has been described recently in two PTC cases from areas contaminated by the Chernobyl nuclear accident (10) . RET/PTC1 and RET/PTC3 arise from chromosome 10 inversions (11, 12) , whereas the rarer RET/ PTC2 arises from a chromosome 10/17 translocation (4). The rearrangements result in constitutive activation of RET, which is phosphorylated on tyrosine and translocated from the membrane to the cytoplasm (13) .
The prevalence of the RET/PTC rearrangements varies widely in different studies (14 -16) , but is generally higher in PTCs from younger patients (17) (18) (19) and in patients exposed to radiation before the development of their PTC (16, 17, 20, 21) . RET/PTC3 is more prevalent than RET/PTC1 in the Chernobyl-associated childhood PTCs (17, 22) . A recent study has demonstrated RET/PTCs, predominantly RET/PTC1, in 84% of PTCs and also in 45% of thyroid follicular adenomas from French patients previously exposed to external radiation (not from Chernobyl) (16) . Before this, RET/PTC was generally thought to be unique to PTC. Furthermore, some of the apparent variation in RET/PTC prevalence may be due to methodology. Some investigators have inferred RET activation by the presence of RET tyrosine kinase (TK) domain messenger ribonucleic acid (mRNA) in PTCs (18) . Others examine for the presence of RET/PTC directly by RT-PCR of the chimeric RNA (17, 22) .
It has been suggested that the presence of RET/PTC in a tumor may predict its clinical behavior (14, 15, 23, 24) , but this requires further clarification.
We examined prospectively the prevalence of specific RET/PTC sequence rearrangements and RET TK domain sequence expression by RT-PCR in 50 PTCs from adult patients. We correlated the genetic findings with any history of radiation exposure and with the MACIS clinical score (25) as well as with individual clinical parameters to determine whether the presence or absence of RET/PTC expression was associated with clinical outcome in patients with PTC.
Subjects and Methods Patients
PTCs were collected prospectively, frozen in liquid nitrogen at the time of thyroidectomy, and stored subsequently at Ϫ70 C. The patients were 50 adults in whom the diagnosis of PTC was confirmed with formal histology of adjacent tissue. Clinical features in these patients and any history of prior exposure to ionizing radiation were noted and recorded in a database. All patients gave informed consent.
The MACIS clinical score and clinical prognostic parameters
The patients were divided into two genetic groups, those with a RET rearrangement in their tumor vs. those without, and into two clinical groups, those with MACIS scores less than 7 (where the 20-yr causespecific survival is 89% or greater) and those with MACIS scores of 7 or more (where the 20-yr survival is 56% or less) (25) . Two-tailed Fisher's exact test was used to analyze any association between the genetic and clinical groups. In addition, any association between either of the genetic groups and individual clinical parameters was analyzed. The MannWhitney test was used to correlate age and tumor size with genetic findings, and Fisher's exact test was used to correlate local invasion, lymph node involvement, and distant metastases with genetic findings.
RT-PCR
RNA was extracted from the tumors (and from the control cell line, TPC-1), using Tri-Reagent (Molecular Research Center, Inc.). RT-PCR was performed using two different pairs of primers specific for RET/ PTC1 and two different combinations of primers for RET/PTC2 and RET/PTC3 (see Table 2 ). One microgram of total RNA from each tumor was reverse transcribed in a volume of 30 L containing 10 mm Trischloride, 50 mm potassium chloride, 2.5 mm Mg chloride, deoxy-NTPs (Boehringer Mannheim, Indianapolis, IN), 0.7 pmol reverse primer, 33 mm dithiothreitol (Life Technologies, Grand Island, NY), 12 U RNasin, (Promega Corp., Madison, WI), and 40 U Superscript reverse transcriptase (Life Technologies). The reaction was performed at 42 C for 30 min, denatured at 95 C for 5 min, and placed on ice. The volume was then increased to 50 L by the addition of 0.7 pmol forward primer and 2.5 U Taq polymerase (Perkin-Elmer Corp., Norwalk, CT). Amplification of the complementary DNA was carried out with 40 cycles of denaturation at 94 C for 30 s, annealing at 55 to 63 C for 1 min, and extension at 72 C for 1 min. RNA from the TPC-1 cell line (containing the RET/PTC1 rearrangement) along with cloned vectors containing RET/PTC2 and RET/PTC3 rearranged genes were used as positive controls and were all obtained from Dr. S. Jhiang (Columbus, OH). RT-PCR using primers for RET TK domain (exons 12-13 and exons [15] [16] [17] was performed on all samples, as was RT-PCR for RET extracellular (exon 2 and exons 7 and 8) and transmembrane domain (exons 11-13). All samples were screened for calcitonin expression by RT-PCR to help exclude the presence of C cells that express RET. RNA integrity was confirmed in all samples with RT-PCR for ␤ 2 -microglobulin. Two negative controls were included in every reaction (Fig. 1) .
Sequencing
All samples positive for a RET rearrangement and all RET TK-positive samples were sequenced using the dideoxy-DNA T7 Sequenase kit (U.S. Biochemical Corp.-Amersham).
Results

Patients
A summary of the clinical data for the 50 patients is given in Table 1 . Three of these 50 patients (aged 32, 35, and 42 yr) had a history of exposure to significant external beam head and neck irradiation at less than 15 yr of age before the diagnosis of PTC, for acute leukemia, for a cerebral tumor, and for cystic acne, respectively. (Table 2) , which binds in gene H4, was used for sequencing across the H4/RET junction.
FIG. 2. RT-PCR products for RET/PTC2
in lanes 1-4 (primers 12 and 8; Table 2 ) and RET/PTC3 in lanes 5-7 (primers 13 and 8; Table  2 
RET/PTC analysis
RT-PCR demonstrated RET/PTC1 in 4 of 50 tumors (8%; Fig. 1A ). This finding was confirmed by sequencing the PCR product, including the segment encompassing the H4/RET junction (Fig. 1B) . Two of the 4 patients whose tumors exhibited RET/PTC1 were exposed to radiation in childhood or adolescence. The prevalence of RET/PTC1 positivity in the subgroup of 3 radiation-exposed patients was, thus, 2 of 3 (66.6%), which is significantly higher than the prevalence in nonirradiated patients of 2 of 47 (4.2%; P ϭ 0.014).
No tumors contained the RET/PTC2 or RET/PTC3 rearrangements (Fig. 2) . Different primer sets for each rearrangement gave concordant results.
RET TK domain mRNA detected by RT-PCR using primers in exons 12 and 13 of RET was present in 35 of 50 (70%) of the PTCs (Fig. 3A) , including all 4 of the tumors in which the RET/PTC1 rearrangement was demonstrated. In contrast, RT-PCR with primers in RET exons 15 and 17 was positive in 12 of 50 (24%) cases (Fig. 3B) . The specificity of the RET TK PCR products was confirmed in all positive cases by sequencing.
Possible reasons for the discordance between the expression of RET/PTC1 mRNA and RET TK mRNA, including the presence of C cells in the tumor specimen, were examined. Calcitonin mRNA was not detected by RT-PCR in any of the tumor specimens (Fig. 4) . Furthermore, no tumors demonstrated RET mRNA expression using a primer pair amplifying RET exons 11-13 or using primers in the RET extracellular domain in exon 2 and exons 7 and 8 (Fig. 5) . Thus, RT-PCR in no case detected endogenous RET extracellular domain mRNA expression despite the high prevalence of RET TK mRNA expression.
Clinical analysis
There was no significant difference between the two clinical patient groups (MACIS score, Ͻ7 vs. Ն7) with respect to Table 2 ). The expected product size of 401 bp is shown by the positive control, medullary thyroid carcinoma (MTC), in lane 2. Lane 1 contains RNA from normal thyroid, lanes 3-6 are PTCs that do not demonstrate calcitonin expression, and lane C1 is a negative control. the presence or absence of RET/PTC in the patient's tumor or indeed with respect to the presence or absence of RET TK domain expression in the tumor, as assessed by RT-PCR using either the exon 12/13 or the exon 15/17 primers. Furthermore, there was no association between any individual clinical parameters, including age, tumor size, local invasion, lymph node involvement, or distant metastases, and the presence or absence of RET/PTC.
Discussion
The prevalence of RET/PTC rearrangements in PTC series from around the world varies widely from approximately 3% (26) to 85% (16) and may be influenced by a number of factors. Exposure to radiation and younger age of onset of PTC are each associated independently with a higher prevalence (17, 19, 22) , and studies of PTC from the Chernobyl area describe a RET/PTC prevalence of the order of 70% (20 -22) .
In our series, RET/PTC rearrangements were found in only 4 of 50 (8%) adult PTCs, and 2 of the RET/PTC positive tumors were from the subgroup of 3 radiation-exposed patients. RET/PTC3 is more prevalent than RET/PTC1 in Chernobyl-associated PTCs (17, 22) , but not in other radiationassociated PTC series (16) . In our study, all rearrangements were RET/PTC1, and in the recent French study of radiationexposed patients with PTCs not associated with Chernobyl, the rearrangements were predominantly RET/PTC1. There are very few such studies of RET/PTC in PTCs of adults with prior radiation exposure not linked to Chernobyl.
RET/PTC analysis is most commonly performed using RT-PCR. A previous study used the fact that RET mRNA is not normally expressed in thyroid follicular cells or PTCs, and the ability to amplify RET TK domain in PTCs was taken as an indication of RET activation (18) . One must be confident that there is no C cell contamination from normal thyroid or low level "normal" RET expression in PTC to draw this conclusion.
There was a large and unexpected discrepancy between the numbers of tumors in which the RET TK exon 12/13 domain was amplified (35 of 50) and those that contained definite RET/PTC rearrangements (4 of 50). There was a smaller, but not insignificant, discrepancy between those in which the RET TK exon 15/17 domain was amplified (12 of 50) and those that contained a RET/PTC rearrangement (4 of 50). Nikiforov et al. have also reported this phenomenon, but to a lesser extent (17) .
These discrepancies do not appear to be due to C cell contamination of tumor samples, as calcitonin mRNA could not be amplified from any tumor sample. Furthermore, neither the RET mRNA extracellular domain nor the RET transmembrane domain could be amplified in the samples that were TK positive. Possible explanations for this are the amplification of other TKs with high homology to RET or the existence of other as yet unidentified RET rearrangements. Primers used for RT-PCR of both RET TK domains were highly specific for RET, and sequencing of the TK-positive tumors showed the TK domain to be RET TK in all cases. These observations make the explanation of cross-homology with other TKs unlikely. Nevertheless, it seems most likely that low level RET expression accounts for the TK expression. Preliminary analysis of other non-PTC tissues, such as follicular adenomas, suggests that RET TK expression is common when using RT-PCR with either TK primer set (data not shown). This does not, however, explain why expression of the RET exon 12/13 TK domain is more frequent than expression of the exon 15/17 TK domain or indeed of the RET extracellular domain. It is possible that the amplification reaction efficiencies differ, so that low levels of expression may be detected by one set of primers but not by another. Low sample availability precluded the use of Southern analysis to detect genomic rearrangements and also prevented further analysis of the upstream sequence of the TKpositive tumors by other techniques.
There is much interest in finding genetic markers that predict the behavior of thyroid tumors, as histological features alone may fail to do so. It has been suggested that the presence of RET/PTC may be associated with a greater likelihood of metastatic spread and poorer prognosis (23) . It has also been suggested, however, that RET/PTC positivity correlates with smaller tumor size and early lymph node spread but lower metastatic potential (14, 24) . The small number of tumors with RET/PTC and the short follow-up period in such studies make statistically significant conclusions on long term prognosis difficult. In our study, there was no significant difference in the MACIS scores or in individual clinical parameters in those patients with RET/PTC rearrangements in their tumors vs. those without. There were, however, only four patients with tumors containing RET/PTC. Prospective collaborative studies will need to be performed to determine whether specific genetic changes such as RET/PTC have prognostic significance.
RET/PTC rearrangements are relatively uncommon in this study of adult PTC, but are more prevalent in the subgroup of patients exposed to radiation in childhood. RET/PTC1 is Table 2 ). RET exons 7 and 8 are shown in lanes 4 -6 (primers 3 and 4; Table 2 ). RT-PCR products for RET exons 11-13 (primers 5 and 9; Table 2 ) are shown in lanes 7-9.
the most common form of RET/PTC in PTCs from adults with a history of external beam irradiation in childhood. This contrasts with PTCs associated with the Chernobyl nuclear accident, where RET/PTC3 is more common.
RET TK domain mRNA expression detected by RT-PCR is a frequent finding in PTCs and cannot be used to infer the presence of specific RET/PTC rearrangements, or indeed of RET activation.
